ReviewClinical imaging2022
COVID-19-induced pulmonary sarcoid: A case report and review of the literature.
Review in Clinical imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Post-COVID-19-Associated Asymptomatic Sarcoidosis with Hypercalcemia and Renal Dysfunction: A Case Report and Literature Review.The American journal of case reports · 2025Review
- Imaging, Pulmonary Function, and Histopathologic Findings of Persistent Fibrosis in a Longitudinal Cohort 3 Years after COVID-19.Annals of the American Thoracic Society · 2025Article
- Granulomatous interstitial nephritis due to sarcoidosis following SARS-CoV-2 infection: a rare case report.CEN case reports · 2025Article
- Prevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- Sarcoidosis in a young adult: A rare sequelae of COVID-19 infection.Clinical case reports · 2024Article
- New-onset sarcoidosis in a patient with long COVID.Clinical case reports · 2024Article
- Incidence, management and prognosis of new-onset sarcoidosis post COVID-19 infection.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- Post-COVID-19 Granulomatous Inflammation in the Lung, Distinct From Sarcoidosis: A Report of Two Cases.Cureus · 2023Article
- Sarcoidosis following COVID infection: A case series.Respirology case reports · 2023Article
- SARS-CoV-2 Infection-Induced Necrotising Sarcoid Granulomatosis.Mediterranean journal of rheumatology · 2023Article
- Gastric Sarcoidosis Flare After Years of Remission Following COVID Infection.Digestive diseases and sciences · 2023Article
- The first reported case of erythrodermic sarcoidosis with systemic involvement during COVID-19 vaccination.Dermatology reports · 2023Article
- Sarcoidosis Presenting as a Lung Mass in a Patient With COVID-19 Infection: A Case Report.Cureus · 2023Article
- Sarcoidosis-related autoimmune inflammation in COVID-19 convalescent patients.Frontiers in medicine · 2023Review
- Can Coronavirus Disease 2019 Induce Sarcoidosis: A Case Report.Thoracic research and practice · 2023Article
- Sarcoidosis and COVID-19: At the Cross-Road between Immunopathology and Clinical Manifestation.Biomedicines · 2022Review
- Can infections trigger sarcoidosis?Clinical imaging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe COVID-19 pandemic has resulted in dramatic loss of life worldwide, but as the large number of acutely ill patients subsides, the emerging group of "COVID-19 long-haulers" present a clinical challenge. Studies have shown that many of these patients suffer long-term pulmonary disease related to residual fibrosis. Prior studies have shown that while many patients have non-specific findings of fibrotic-like changes, others develop specific patterns of interstitial lung disease. CASE REPORT: Here, we present the first case of a patient developing pulmonary sarcoidosis one year after critical illness from COVID-19. He developed numerous non-necrotizing and well-formed granulomas in mediastinal lymph nodes and pulmonary nodules, compatible radiographically and pathologically with sarcoid.
conclusionsWhile the pathophysiology of sarcoid is incompletely understood, inflammation is mediated through the dysregulation of a number of different cytokines (IFNγ, IL-2, IL-12, IL-17, IL-22). This case provides valuable clues for better understanding of the shared pathophysiology of cytokine dysregulation seen in COVID-19 and other interstitial lung diseases such as sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.